OBJECTIVES: Emergence and spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae remain a major global problem and expanded, but valid, AMR surveillance is crucial for public health purposes. The World Health Organization (WHO) Collaborating Centre in Sydney, Australia, continually evaluates N. gonorrhoeae strains used in quality control and assurance aspects of the national, WHO regional and international programmes for AMR surveillance it conducts. Here we phenotypically and genetically characterized the 2008 WHO N. gonorrhoeae reference panel, widely used under existing WHO AMR surveillance protocols. MATERIALS AND METHODS: The eight N. gonorrhoeae WHO reference strains were phenotypically characterized by antibiogram, auxotype, serovar and prolyliminopeptidase screening; and genetically with regard to resistance plasmid types, polymorphisms in divergent genetic resistance-mediating loci (n = 9), porB sequencing and N. gonorrhoeae multi-antigen sequence typing. RESULTS: The 2008 WHO reference strains represented all the important susceptible and resistant phenotypes, including corresponding resistance genotypes, and the range of resistances currently seen for relevant antimicrobials. Several pertinent additional phenotypic and genotypic markers, for example, epidemiological markers, were also determined. CONCLUSIONS: The 2008 WHO N. gonorrhoeae reference strain panel was extensively characterized, which is crucial for the expansion of gonococcal AMR surveillance nationally and internationally. The panel is available through WHO sources for quality assurance and quality control aspects of current phenotypic testing protocols, to allow valid comparison of AMR data derived by divergent methods, and also for the control of present and future molecular assays for AMR detection. Additional WHO reference strains can be included as required by the emergence of additional resistant phenotypes and/or genotypes.
OBJECTIVES: Emergence and spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae remain a major global problem and expanded, but valid, AMR surveillance is crucial for public health purposes. The World Health Organization (WHO) Collaborating Centre in Sydney, Australia, continually evaluates N. gonorrhoeae strains used in quality control and assurance aspects of the national, WHO regional and international programmes for AMR surveillance it conducts. Here we phenotypically and genetically characterized the 2008 WHO N. gonorrhoeae reference panel, widely used under existing WHO AMR surveillance protocols. MATERIALS AND METHODS: The eight N. gonorrhoeae WHO reference strains were phenotypically characterized by antibiogram, auxotype, serovar and prolyliminopeptidase screening; and genetically with regard to resistance plasmid types, polymorphisms in divergent genetic resistance-mediating loci (n = 9), porB sequencing and N. gonorrhoeae multi-antigen sequence typing. RESULTS: The 2008 WHO reference strains represented all the important susceptible and resistant phenotypes, including corresponding resistance genotypes, and the range of resistances currently seen for relevant antimicrobials. Several pertinent additional phenotypic and genotypic markers, for example, epidemiological markers, were also determined. CONCLUSIONS: The 2008 WHO N. gonorrhoeae reference strain panel was extensively characterized, which is crucial for the expansion of gonococcal AMR surveillance nationally and internationally. The panel is available through WHO sources for quality assurance and quality control aspects of current phenotypic testing protocols, to allow valid comparison of AMR data derived by divergent methods, and also for the control of present and future molecular assays for AMR detection. Additional WHO reference strains can be included as required by the emergence of additional resistant phenotypes and/or genotypes.
Authors: Raymond Heymans; Daniel Golparian; Sylvia M Bruisten; Leo M Schouls; Magnus Unemo Journal: J Clin Microbiol Date: 2011-11-09 Impact factor: 5.948
Authors: Jan van de Kassteele; Marga G van Santen-Verheuvel; Femke D H Koedijk; Alje P van Dam; Marianne A B van der Sande; Albert J de Neeling Journal: Antimicrob Agents Chemother Date: 2012-01-09 Impact factor: 5.191
Authors: Pam Sawatzky; Gary Liu; Jo-Anne R Dillon; Vanessa Allen; Brigitte Lefebvre; Linda Hoang; Greg Tyrrell; Paul Van Caeseele; Paul Levett; Irene Martin Journal: J Clin Microbiol Date: 2015-09-02 Impact factor: 5.948
Authors: Magnus Unemo; Daniel Golparian; Leonor Sánchez-Busó; Yonatan Grad; Susanne Jacobsson; Makoto Ohnishi; Monica M Lahra; Athena Limnios; Aleksandra E Sikora; Teodora Wi; Simon R Harris Journal: J Antimicrob Chemother Date: 2016-07-17 Impact factor: 5.790
Authors: S W Peterson; I Martin; W Demczuk; A Bharat; L Hoang; J Wylie; V Allen; B Lefebvre; G Tyrrell; G Horsman; D Haldane; R Garceau; T Wong; M R Mulvey Journal: J Clin Microbiol Date: 2015-04-15 Impact factor: 5.948
Authors: Vanessa G Allen; David J Farrell; Anuradha Rebbapragada; Jingyuan Tan; Nathalie Tijet; Stephen J Perusini; Lynn Towns; Stephen Lo; Donald E Low; Roberto G Melano Journal: Antimicrob Agents Chemother Date: 2010-11-22 Impact factor: 5.191
Authors: Fadi E El-Rami; Ryszard A Zielke; Teodora Wi; Aleksandra E Sikora; Magnus Unemo Journal: Mol Cell Proteomics Date: 2018-10-23 Impact factor: 5.911
Authors: David Hess; Abel Wu; Daniel Golparian; Sarah Esmaili; Will Pandori; Emilee Sena; Jeffrey D Klausner; Pennan Barry; Magnus Unemo; Mark Pandori Journal: Antimicrob Agents Chemother Date: 2012-08-20 Impact factor: 5.191